Similarly, for the 3639 ER+ cases that had at least 5 years of survival time, the univariate Cox regression analysis showed a borderline significant estimate of 15% worse survival in ER+ ILC compared to ER+ IDC (95% CI: 1.00, 1.32), but this association was no longer significant when adjusted by nodal status, tumour size, grade, age at diagnosis, HER2 status, and chemotherapy (OR: 0.97, 95% CI: 0.83, 1.12) (Table S1). This evidence concerns the gene ERBB2 and neoplasm.